Atara Biotherapeutics (ATRA) AI Stock Analysis

• Market Cap: $98.64M
• Dividend Yield: N/A
• Average Volume (3M): 59.31K
• Price to Earnings (P/E): 6.2
• Beta (1Y): 0.64
• Revenue Growth: 51.27%
• EPS Growth: N/A
• Country: US
• Employees: 153
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.19
• Shares Outstanding: 7,210,235
• 10 Day Avg. Volume: 58,829
• 30 Day Avg. Volume: 59,307
• PEG Ratio: 0.01
• Price to Book (P/B): -1.02
• Price to Sales (P/S): 0.77
• P/FCF Ratio: -1.45
• Enterprise Value/Market Cap: 1.33
• Enterprise Value/Revenue: 0.86
• Enterprise Value/Gross Profit: 1.06
• Enterprise Value/Ebitda: 4.30
• 1Y Price Target: $17.50
• Price Target Upside: 10.83% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 2.43
• Revenue Forecast (FY): $121.21M

• Rating: 52 Neutral
• Price Target: $13.00 ▼(-17.67% Downside)

Atara Biotherapeutics faces significant financial challenges, with declining revenues and negative equity being major concerns. The technical analysis shows a bearish trend, while the valuation suggests the stock might be undervalued. The lack of earnings call data and corporate events limits additional insights.

Positive Factors

Strategic Partnerships

The partnership with Pierre Fabre Pharmaceuticals for tabelecleucel's BLA transfer indicates strategic collaboration, potentially enhancing Atara's global reach and leveraging PFP's resources for regulatory and commercial success.

Innovative Product Pipeline

Atara's focus on innovative T-cell therapies positions it well in the biotechnology sector, offering potential breakthroughs in treating cancer and autoimmune diseases, which could drive long-term growth.

High Gross Profit Margin

A high gross profit margin indicates efficient cost management and potential for profitability, providing a strong foundation for future financial health as revenue streams stabilize.

Negative Factors

Negative Revenue Growth

Negative revenue growth reflects challenges in maintaining sales levels, which could hinder the company's ability to fund R&D and operational activities, impacting long-term sustainability.

Financial Instability

Negative equity and financial instability can limit Atara's ability to invest in growth opportunities and may lead to increased reliance on external funding, affecting long-term viability.

Cash Flow Challenges

Negative cash flows indicate difficulties in generating sufficient cash from operations, which can constrain Atara's ability to invest in R&D and strategic initiatives, impacting future growth prospects.

Atara Biotherapeutics Business Overview & Revenue Model

Company Description

Atara Biotherapeutics (ATRA) is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients with serious diseases, particularly cancer and autoimmune disorders. The company operates primarily in the biopharmaceutical sector, leveraging advanced science to create T-cell therapies that harness the body's immune system to target and eradicate disease. Atara's core products include its lead investigational therapies, which utilize allogeneic T-cell immunotherapy derived from donor cells, aimed at treating various malignancies and chronic viral infections.

How the Company Makes Money

Atara Biotherapeutics generates revenue primarily through collaborations, grants, and clinical trial partnerships. The company may receive milestone payments and royalties from strategic partnerships with larger pharmaceutical companies that help fund its research and development efforts. Significant partnerships can include co-development agreements or licensing deals, where Atara provides its technology and expertise in exchange for financial support and shared profits on future product sales. Additionally, the company may receive funding from government grants or public and private investors, particularly for its innovative therapies that address unmet medical needs.

Atara Biotherapeutics Financial Statement Overview

Summary

Atara Biotherapeutics faces significant financial challenges. Despite a high gross profit margin, the company struggles with low net profit margins and negative revenue growth. The balance sheet shows financial instability with negative equity, and cash flow issues are evident with negative operating and free cash flows.

Income Statement

Atara Biotherapeutics shows a mixed performance in its income statement. The company has a positive gross profit margin of 79.32% TTM, indicating efficient cost management relative to revenue. However, the net profit margin is low at 3.39% TTM, and revenue growth is negative at -5.54% TTM, reflecting challenges in maintaining revenue levels. The EBIT and EBITDA margins are modest at 3.85% and 8.13% TTM, respectively, suggesting limited operational profitability.

Balance Sheet

The balance sheet reveals significant financial instability. The company has a negative stockholders' equity, leading to a negative debt-to-equity ratio of -0.44 TTM, which is concerning. The return on equity is also negative, indicating losses relative to shareholder investments. The equity ratio is not directly calculable due to negative equity, highlighting potential solvency issues.

Cash Flow

Cash flow analysis shows a challenging situation with negative operating and free cash flows. The free cash flow growth rate is negative at -4.98% TTM, and the operating cash flow to net income ratio is -4.39 TTM, indicating cash flow issues relative to earnings. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is marginally covering net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	151.93M	128.94M	8.57M	63.57M	20.34M	0.00
Gross Profit	124.03M	107.93M	-313.00K	63.57M	-261.66M	-244.65M
EBITDA	30.50M	-75.75M	-266.00M	-222.26M	-331.12M	-300.72M
Net Income	23.40M	-85.40M	-276.13M	-228.30M	-340.14M	-306.62M
Balance Sheet
Total Assets	30.17M	109.10M	165.50M	376.42M	468.13M	588.12M
Cash, Cash Equivalents and Short-Term Investments	13.71M	42.50M	51.73M	242.82M	371.07M	500.66M
Total Debt	58.60M	43.83M	57.87M	71.70M	28.27M	15.03M
Total Liabilities	66.80M	206.38M	264.74M	249.78M	188.51M	125.78M
Stockholders Equity	-36.63M	-97.28M	-99.23M	126.64M	279.61M	462.34M
Cash Flow
Free Cash Flow	-69.80M	-68.96M	-194.20M	-274.62M	-231.10M	-185.27M
Operating Cash Flow	-69.71M	-68.72M	-192.98M	-270.43M	-220.52M	-180.76M
Investing Cash Flow	13.08M	8.62M	123.87M	202.96M	22.26M	-120.73M
Financing Cash Flow	15.77M	59.28M	2.01M	53.08M	103.94M	427.57M

Atara Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.79
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATRA, the sentiment is Positive. The current price of 15.79 is above the 20-day moving average (MA) of 13.22, above the 50-day MA of 13.83, and above the 200-day MA of 9.96, indicating a bullish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 53.62 is Neutral, neither overbought nor oversold. The STOCH value of 62.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATRA.

Atara Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATRA	52 Neutral	$98.64M	6.24	―	―	51.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADVM	49 Neutral	$90.96M	-0.48	-417.79%	―	-100.00%	-42.12%
ZNTL	46 Neutral	$100.43M	-0.67	-49.18%	―	-33.76%	17.54%
MGNX	45 Neutral	$89.83M	―	-81.13%	―	-9.70%	23.23%
SRZN	43 Neutral	$107.90M	-0.90	―	―	-63.96%	-28.50%
TCRX	41 Neutral	$56.19M	-0.88	-76.44%	―	-10.03%	11.06%

Atara Biotherapeutics Corporate Events

Atara Biotherapeutics Announces Significant Workforce Reduction

On October 6, 2025, Atara Biotherapeutics announced a workforce reduction affecting about 29% of its employees, with the aim of aligning its operations with strategic priorities. The company anticipates incurring approximately $1.3 million in severance and related benefits, with completion expected by January 2026, and further financial details to be disclosed in their upcoming quarterly report.

The most recent analyst rating on (ATRA) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

Atara Biotherapeutics Reduces Board Size, Appoints New Chair

On September 2, 2025, Atara Biotherapeutics announced a strategic reduction in its Board of Directors from ten to seven members to better align with its current operations and the boards of similar-sized public companies. This decision led to the voluntary resignation of directors Ameet Mallik, Pascal Touchon, and Maria Grazia Roncarolo, M.D., with Gregory A. Ciongoli being appointed as the new Chair of the Board, replacing Pascal Touchon.

The most recent analyst rating on (ATRA) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.